The $200 Billion Problem
How AI Is Rewriting Drug Discovery and Closing Pharma's Patent Cliff
The pharmaceutical industry is caught between a financial crisis and a scientific revolution. Between now and 2030, patent protections will expire on drugs generating more than $200 billion in annual revenue, three times the size of the previous patent cliff. At the same time, artificial intelligence is being deployed across every stage of how drugs are discovered and developed. This book traces the collision of those two forces, examines the Prediction Stack framework for understanding where drug discovery fails, and maps the convergence of technology companies, pharmaceutical giants, and venture capital betting hundreds of billions on AI being the answer.
What You'll Learn
The Patent Cliff
$200+ billion in annual drug revenue loses patent protection between 2025-2030. About 70 blockbusters, each generating over $1B/year. Three times the size of the previous cliff.
The Prediction Stack
A three-layer framework for understanding where prediction fails in drug discovery, at target selection, molecular design, and clinical outcomes, and how AI addresses each layer.
The Cost of Being Wrong
Most of the $2.6 billion average cost of an approved drug is not the cost of doing science. It is the cost of being wrong, compounded across thousands of failed compounds.
173+ AI Programs in Clinical Development
As of early 2026, at least 173 AI-discovered drug programs are in clinical development. The direction is unmistakable.
The Platform Companies
Recursion, Insilico Medicine, and Isomorphic Labs are building end-to-end AI drug discovery platforms. NVIDIA, Google DeepMind, and Anthropic are providing the computational infrastructure.
Table of Contents
Part I — The Burning Platform
The Cliff Edge
The Old Way is Dying
Too Slow, Too Expensive, Too Late
Part II — The AI Arsenal
The Machine That Reads Biology
Designing Molecules in Silico
The Digital Twin Lab
Smarter Trials, Faster Results
The Regulatory Intelligence Layer
Part III — The Ecosystem
From Discovery to Wet Lab: Closing the Loop
The Data Problem Nobody Talks About
The Platform Companies Changing the Game
Big Pharma's AI Bets
The Goliaths Enter the Lab: NVIDIA, Google, Anthropic & the Quantum Frontier
Part IV — The Human Dimension
The Scientist and the Algorithm
The Ethics of Speed
The Cost Revolution
Part V — The Horizon
The 5-Year Drug
Who Wins, Who Loses
The $200 Billion Answer
Who This Book Is For
Pharmaceutical executives and R&D leaders
Biotech founders and investors
Healthcare and life sciences strategists
Technology leaders entering pharma
Anyone interested in the future of drug discovery